After serving as a member of the clinical faculty at the UCSF School of Pharmacy for over 13 years, Dr. Flaherty transitioned to a career in the pharmaceutical industry in 1998. Over the past 23+ years he has held various positions of increasing responsibility within Medical Affairs and Clinical Research at Gilead Sciences. Currently, he is Executive Director, Clinical Development, and oversees the viral hepatitis treatment programs in HBV, HCV, and HDV, including Development Lead for tenofovir alafenamide (Vemlidy) and bulevirtide (Hepcludex). Dr. Flaherty is the author of 78 peer-reviewed journal articles and has received numerous awards and honors. In his spare time, he enjoys spending time with family, including his 3 grandchildren, and pursuing hobbies that include travel, surfing, yoga, and enjoying good food and fine wines.
